Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

9.695 -0.125 (-1.27%)

Delayed Quote Updated: 3:31 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

July 09, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

June 24, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

June 23, 2025

Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 06, 2025

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy ↗

May 28, 2025

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Via Stocktwits

Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? ↗

May 28, 2025

Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results.

Via Benzinga

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish ↗

May 13, 2025

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Via Stocktwits

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics to Present at Upcoming Investor Conferences

May 06, 2025

From Candel Therapeutics

Via GlobeNewswire

Top movers in Wednesday's after hours session ↗

April 23, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 23, 2025

Via Benzinga

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

April 23, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

April 01, 2025

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients ↗

March 27, 2025

Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.

Via Benzinga

Candel Therapeutics Shares Are Down Today: What's Going On? ↗

March 27, 2025

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

Via Benzinga

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism ↗

March 27, 2025

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.

Via Stocktwits

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

March 20, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

March 26, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

March 18, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 13, 2025

From Candel Therapeutics

Via GlobeNewswire

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

February 25, 2025

From Candel Therapeutics

Via GlobeNewswire

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗

February 23, 2025

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Via Stocktwits

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 20, 2025

Via Benzinga

Major Indexes Falter; Dow Drops Over 550 Points ↗

February 20, 2025

The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well.

Via Talk Markets

Topics Stocks Stocks / Equities

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 20, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice ↗

February 20, 2025

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.

Via Stocktwits

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

February 19, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.